In addition, we also found the abundance of the B cell demonstrated positive correlation with ICB response for UC patients, and also achieved preferable predictive performance in ccRCC and in melanoma patients treated with anti-CTLA-4 therapy. The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.